TLTang Ching Lau

Tang Ching Lau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tang Ching Lau has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Gim Gee Teng

    Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore

    3 shared publications
  • Sok Ying Liaw

    Alice Lee Centre for Nursing Studies Yong Loo Lin School of Medicine National University of Singapore Singapore

    3 shared publications
  • Chiang Siau

    Yong Loo Lin School of Medicine, National University of Singapore, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260; Centre for Healthcare Simulation, National University of Singapore, 14 Medical Drive, Block MD6, 03-01, Singapore

    2 shared publications
  • Peter Pak Moon Cheung

    Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore

    2 shared publications
  • Wentao Zhou

    Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

    2 shared publications
  • Anita Y. N. Lim

    Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore

    1 shared publication

Latest Publications

  • Learning during the pandemic: Perspectives of medical students in Singapore

    by Isaac Ks Ng, Valencia Ry Zhang, Fan Shuen Tseng, Desiree Sh Tay, Shuh Shing Lee, Tang Ching Lau

    The COVID-19 pandemic has significantly disrupted medical education, particularly affecting clinical-year students. Educational institutions often had to halt, shorten or impose significant restrictions on their hospital rotations due to strict infection control and social-distancing guidelines implemented in tertiary healthcare institutions, as well as manpower and logistical constraints amid the pandemic. Thus, distance-based learning platforms such as online lectures and case-based teaching were increasingly adopted in place of bedside and face-to-face tutorials. While interactive virtual case-based discussions are generally useful in imparting clinical reasoning skills to medical students, they are unfortunately not able to fully replicate the experience of clerking, examining and managing real patients in the wards, which is a quintessential process towards building clinical acumen and attaining core clinical competencies. Therefore, for final year medical students who are preparing for their Bachelor of Medicine and Bachelor of Surgery (MBBS) examinations, many are naturally concerned by how learning in this "new normal" may affect their ability to make the transition to become competent junior doctors. As such, we seek to share our learning experiences as the first batch of medical students to have completed our entire final year of clinical education amid the COVID-19 pandemic, and offer 4 practical suggestions to future batches of students on how to adapt and optimise clinical learning under these circumstances: actively engaging in virtual learning, making the most of every clinical encounter, learning how to construct peer teaching/practice sessions, and maintaining physical and psychological well-being.


  • Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti‐rheumatic agents for the treatment of psoriatic arthritis

    by Manjari Lahiri, Gim‐Gee Teng, Peter P. Cheung, Ernest Suresh, Faith L. Chia, Nai‐Lee Lui, Dow‐Rhoon Koh, Wei‐Howe Koh, Khai‐Pang Leong, Anita Y. N. Lim, et al.

    In Singapore, patients with psoriatic arthritis (PsA) constitute a significant disease burden. There is good evidence for the efficacy of anti-tumor necrosis factor (anti-TNF) in PsA; however cost remains a limiting factor. Non-biologic disease modifying anti-rheumatic drugs (nbDMARDs) hence remain the first-line treatment option in PsA in spite of limited evidence. The Singapore Chapter of Rheumatologists aims to develop national guidelines for clinical eligibility for government-assisted funding of biologic disease modifying anti- rheumatic drugs (bDMARDs) for PsA patients in Singapore. Evidence synthesis was performed by reviewing seven published guidelines on use of biologics for PsA. Using the modified Research and Development/University of California at Los Angeles Appropriateness Method (RAM), rheumatologists rated indications for therapies for different clinical scenarios. Points reflecting the output from the formal group consensus were used to formulate the practice recommendations. Ten recommendations were formulated relating to initiation, continuation and options of bDMARD therapy. The panellists agreed that a bDMARD is indicated if a patient has active PsA with at least five swollen and tender joints, digits or entheses and has failed two nbDMARD strategies at optimal doses for at least 3 months each. Any anti-TNF may be used and therapy may be continued if an adequate PsARC response is achieved by 3 months after commencement. The recommendations developed by a formal group consensus method may be useful for clinical practice and guiding funding decisions by relevant authorities in making bDMARD usage accessible and equitable to eligible patients in Singapore.


  • Open Access

    Integrating rheumatology care in the community: can shared care work?

    by Anita Yn Lim, Chuen-Seng Tan, Bernadette Pl Low, Tang-Ching Lau, Tze- Lee Tan, Lee-Gan Goh, Gim-Gee Teng

    Singapore's rapidly ageing population and chronic disease burden at public hospital specialist clinics herald a silver tsunami. In Singapore, “right siting” aims to manage stable chronic disease in primary care at a lower cost. To improve the quality of rheumatology care, we created shared care between rheumatologist and family physician to reduce hospital visits. Clinical practice improvement methodology was used to structure shared care of stable patients between hospital rheumatologists and eleven community family physicians; one ran a hospital clinic. A case manager coordinated the workflow. About 220 patients entered shared care over 29 months. Patients without hospital subsidies (private patients) and private family physicians independently predicted successful shared care, defined as one cycle of alternating care. Our shared care model incorporated a case manager, systematic workflows, patient selection criteria, willing family physician partners and rheumatologists in the absence of organizational integration. Health care affordability impacts successful shared care. Government subsidy hindered right siting to private primary care. Financing systems in Singapore, at health policy level, must allow transfer of hospital subsidies to primary care, both private and public, to make it more affordable than hospital care. Structural integration will create a seamless continuum between hospital and primary care.


  • Singapore Chapter of Rheumatologists Consensus Statement on the Eligibility for Government Subsidy of Biologic Disease Modifying Antirheumatic Agents for Treatment of Rheumatoid Arthritis (RA)

    by Gim Gee Teng, Peter P Cheung, Manjari Lahiri, Jane A Clayton, Li Ching Chew, Ee Tzun Koh, Wei Howe Koh, Tang Ching Lau, Swee Cheng Ng, Bernard Y Thong, et al.

    Up to 30% of patients with rheumatoid arthritis (RA) respond inadequately to conventional non-biologic disease modifying antirheumatic drugs (nbDMARDs), and may benefit from therapy with biologic DMARDs (bDMARDs). However, the high cost of bDMARDs limits their widespread use. The Chapter of Rheumatologists, College of Physicians, Academy of Medicine, Singapore aims to define clinical eligibility for government-assisted funding of bDMARDs for local RA patients. Evidence synthesis was performed by reviewing 7 published guidelines on use of biologics for RA. Using the modified RAND/UCLA Appropriateness Method (RAM), rheumatologists rated indications for therapies for different clinical scenarios. Points reflecting the output from the formal group consensus were used to formulate the practice recommendations. Ten recommendations including diagnosis of RA, choice of disease activity measure, initiation and continuation of bDMARD and option of first and second-line therapies were formulated. The panellists agreed that a bDMARD is indicated if a patient has (1) active RA with a Disease Activity Score in 28 joints (DAS28) score of ≥3.2, (2) a minimum of 6 swollen and tender joints, and (3) has failed a minimum of 2 nbDMARD combinations of adequate dose regimen for at least 3 months each. To qualify for continued biologic therapy, a patient must have (1) documentation of DAS28 every 3 months and (2) at least a European League Against Rheumatism (EULAR) moderate response by 6 months after commencement of therapy. The recommendations developed by a formal group consensus method may be useful for clinical practice and guiding funding decisions by relevant authorities in making bDMARDs usage accessible and equitable to eligible patients in Singapore.


  • An interprofessional communication training using simulation to enhance safe care for a deteriorating patient

    by Sok Ying Liaw, Wen Tao Zhou, Tang Ching Lau, Chiang Siau, Sally Wai-Chi Chan